Lilly announces agreement with U.S. government to supply 300,000 vials of investigational neutralizing antibody bamlanivimab (LY-CoV555) in an effort to fight COVID-19

- Initial agreement for 300,000 vials with potential for purchase of an additional 650,000 vials   - Patients will have no out-of-pocket costs for the medication INDIANAPOLIS , Oct. 28, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) announced today an initial agreement with the U.S.